Skip to main content
. Author manuscript; available in PMC: 2015 Jan 15.
Published in final edited form as: Nanomedicine (Lond). 2012 Sep 3;7(12):1851–1862. doi: 10.2217/nnm.12.70

Figure 5. Biological activity of tripartite nanoconjugates.

Figure 5

(A) The effect of protamine:GNPs incubated with luciferase protein, which were then exposed to A375 cells, and then the cells were rinsed. The cell-associated luminescence activity was quantified. (B) Tuberculosis antigen 85B presentation coculture assay positive controls. For details, see the experimental methods section in [22]. (C) Western blot of B-Raf expression in A375 cells after anti-B-Raf siRNA treatment with delivery by Lipofectamine™ (lipo-NH2)-siRNA, GNP–Prot control or the GNP–Prot–siRNA nanoconjugate. (D) Comparison of methoxypoly(ethylene glycol)-block-polyamidoamine dendrimer and GNP nanoconjugate effect on delivery of B-Raf siRNA. Represents the number of A375 tumor ‘spheroids’ formed after treatment of nanoconjugates. Error bars represent standard deviation values.

Abs.: Absorbance; B-Raf: B-Raf siRNA; Dend: Dendrimer; GNP: Gold nanoparticle; Luc: Luciferase; Prot: Protamine; RLU: Relative light unit.